Related Experiment Video
Updated: Aug 8, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Developing guidelines for biotechnology drug use: experience with antithrombin III
D R Romac1, P Poole, J T Owings
1UC Davis Medical Center, Sacramento, CA 95817, USA.
Abstract:
Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P & T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P & T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.
More Related Videos
06:38The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
Published on: December 19, 2025
08:01The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Drug Analysis Methods
Pharmacogenomics: Identification of New Drug Targets
Venous Thrombosis III: Interprofessional Care